Synaptic and extrasynaptic plasticity in glutamatergic circuits involving dentate granule cells following chronic N-methyl-D-aspartate receptor inhibition

Journal of Neurophysiology

Volumn 109, Issue 6, 2013, Pages 1535-1547

  He, Shuijin ^a   Shao, Li Rong ^a   Wang, Yu ^a   Bausch, Suzanne B ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

AMPA receptor; GluN2A; GluN2B; Hippocampus; NR2A; NR2B; Ro25 6981

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NVP AAM077; UNCLASSIFIED DRUG;

ARTICLE; BRAIN SLICE; DENTATE GYRUS; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; GRANULE CELL; HIPPOCAMPUS; NERVE CELL PLASTICITY; NERVE POTENTIAL; NEUROTRANSMISSION; PRIORITY JOURNAL; SEIZURE;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; DENTATE GYRUS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; MINIATURE POSTSYNAPTIC POTENTIALS; NEURONAL PLASTICITY; NEURONS; PIPERIDINES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 84878490130     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00667.2012     Document Type: Article

References (71)

1. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M. 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12: 1099-1102, 2002.
2. Bausch SB, He S, Dong Y. Inverse relationship between seizure expression and extrasynaptic NMDAR function following chronic NMDAR inhibition. Epilepsia 51, Suppl 3: 102-105, 2010.
3. Bausch SB. Organotypic hippocampal slice cultures as a model of limbic epileptogenesis. In: Neuromethods. Innovations in Epilepsy Research, edited by Baraban SC. New York: Humana, 2009, vol. 40, p. 183-201.
4. Bausch SB, He S, Petrova Y, Wang XM, McNamara JO. Plasticity of both excitatory and inhibitory synapses is associated with seizures induced by removal of chronic blockade of activity in cultured hippocampus. J Neurophysiol 96: 2151-2167, 2006.
5. Bausch SB, McNamara JO. Contributions of mossy fiber and CA1 pyramidal cell sprouting to dentate granule cell hyperexcitability in kainic acid-treated hippocampal slice cultures. J Neurophysiol 92: 3582-3595, 2004.
6. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 51: 7-61, 1999.
7. Bausch SB, McNamara JO. Synaptic connections from multiple subfields contribute to granule cell hyperexcitability in hippocampal slice cultures. J Neurophysiol 84: 2918-2932, 2000.
8. 2 induced epileptiform activity from the rat entorhinal cortex to the hippocampus after kindling studied in vitro. Neurosci Lett 216: 41-44, 1996.
9. Behr J, Lyson KJ, Mody I. Enhanced propagation of epileptiform activity through the kindled dentate gyrus. J Neurophysiol 79: 1726-1732, 1998.
10. Brizzi L, Meunier C, Zytnicki D, Donnet M, Hansel D, D'Incamps BL, Van Vreeswijk C. How shunting inhibition affects the discharge of lumbar motoneurones: a dynamic clamp study in anaesthetized cats. J Physiol 558: 671-683, 2004.
11. Cavelier P, Attwell D. Tonic release of glutamate by a DIDS-sensitive mechanism in rat hippocampal slices. J Physiol 564: 397-410, 2005.
12. Chazot PL, Lawrence S, Thompson CL. Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology 42: 319-324, 2002.
13. Chenard BL, Shalaby IA, Koe BK, Ronau RT, Butler TW, Prochniak MA, Schmidt AW, Fox CB. Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34: 3085-3090, 1991.
14. 2 channels in rat and mouse cultured hippocampal pyramidal neurones: comparison with N-methyl-D-aspartate receptor antagonist actions. Br J Pharmacol 113: 499-507, 1994.
15. Collins RC, Tearse RG, Lothman EW. Functional anatomy of limbic seizures: focal discharges from medial entorhinal cortex in rat. Brain Res 280: 25-40, 1983.
16. Conti F, DeBiasi S, Minelli A, Melone M. Expression of NR1 and NR2A/B subunits of the NMDA receptor in cortical astrocytes. Glia 17: 254-258, 1996.
17. Cope DW, Hughes SW, Crunelli V. GABAA receptor-mediated tonic inhibition in thalamic neurons. J Neurosci 25: 11553-11563, 2005.
18. Dalby NO, Mody I. Activation of NMDA receptors in rat dentate gyrus granule cells by spontaneous and evoked transmitter release. J Neurophysiol 90: 786-797, 2003.
19. Dingledine R, McBain CJ, McNamara JO. Excitatory amino acid receptors in epilepsy. Trends Pharmacol Sci 11: 334-338, 1990.
20. Evans RH, Francis AA, Jones AW, Smith DA, Watkins JC. The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br J Pharmacol 75: 65-75, 1982.
21. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors. Nat Rev Neurosci 6: 215-229, 2005.
22. Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G. Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43: 729-743, 2004.
23. Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br J Pharmacol 141: 508-516, 2004.
24. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, Heitz MP, Kemp JA. Ro 256981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283: 1285-1292, 1997.
25. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci 17: 2469-2476, 1997.
26. Gould E, Cameron HA, McEwen BS. Blockade of NMDA receptors increases cell death and birth in the developing rat dentate gyrus. J Comp Neurol 340: 551-565, 1994.
27. Hardingham GE, Bading H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26: 81-89, 2003.
28. Hatton CJ, Paoletti P. Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 46: 261-274, 2005.
29. He S, Shao LR, Rittase WB, Bausch SB. Increased Kv1 channel expression may contribute to decreased sIPSC frequency following chronic inhibition of NR2B-containing NMDAR. Neuropsychopharmacology 37: 1338-1356, 2012.
30. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74, 1999.
31. Jourdain P, Bergersen LH, Bhaukaurally K, Bezzi P, Santello M, Domercq M, Matute C, Tonello F, Gundersen V, Volterra A. Glutamate exocytosis from astrocytes controls synaptic strength. Nat Neurosci 10: 331-339, 2007.
32. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 5, Suppl: 1039-1042, 2002.
33. Kew JN, Trube G, Kemp JA. A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497: 761-772, 1996.
34. Kohr G, De Koninck Y, Mody I. Properties of NMDA receptor channels in neurons acutely isolated from epileptic (kindled) rats. J Neurosci 13: 3612-3627, 1993.
35. Krebs C, Fernandes HB, Sheldon C, Raymond LA, Baimbridge KG. Functional NMDA receptor subtype 2B is expressed in astrocytes after ischemia in vivo and anoxia in vitro. J Neurosci 23: 3364-3372, 2003.
36. Lalo U, Pankratov Y, Kirchhoff F, North RA, Verkhratsky A. NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. J Neurosci 26: 2673-2683, 2006.
37. Le Meur K, Galante M, Angulo MC, Audinat E. Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. J Physiol 580: 373-383, 2007.
38. Liao D, Zhang X, O'Brien R, Ehlers MD, Huganir RL. Regulation of morphological postsynaptic silent synapses in developing hippocampal neurons. Nat Neurosci 2: 37-43, 1999.
39. Lin SY, Constantine-Paton M. Suppression of sprouting: an early function of NMDA receptors in the absence of AMPA/kainate receptor activity. J Neurosci 18: 3725-3737, 1998.
40. Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 8: 803-808, 2007.
41. Loscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog Neurobiol 54: 721-741, 1998.
42. McCool BA, Lovinger DM. Ifenprodil inhibition of the 5-hydroxytryptamine3 receptor. Neuropharmacology 34: 621-629, 1995.
43. McKinney RA, Luthi A, Bandtlow CE, Gahwiler BH, Thompson SM. Selective glutamate receptor antagonists can induce or prevent axonal sprouting in rat hippocampal slice cultures. Proc Natl Acad Sci USA 96: 11631-11636, 1999.
44. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529-540, 1994.
45. Mori H, Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 34: 1219-1237, 1995.
46. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319: 774-776, 1986.
47. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513, 1995.
48. Neyton J, Paoletti P. Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci 26: 1331-1333, 2006.
49. O'Brien RJ, Kamboj S, Ehlers MD, Rosen KR, Fischbach GD, Huganir RL. Activity-dependent modulation of synaptic AMPA receptor accumulation. Neuron 21: 1067-1078, 1998.
50. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362, 1989.
51. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2: 241-271, 2001.
52. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38: 735-767, 1999.
53. Rao A, Craig AM. Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. Neuron 19: 801-812, 1997.
54. Sah P, Hestrin S, Nicoll RA. Tonic activation of NMDA receptors by ambient glutamate enhances excitability of neurons. Science 246: 815-818, 1989.
55. Scherzer CR, Landwehrmeyer GB, Kerner JA, Counihan TJ, Kosinski CM, Standaert DG, Daggett LP, Velicelebi G, Penney JB Jr, Young AB. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex. J Comp Neurol 390: 75-90, 1998.
56. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832-835, 1992.
57. Semyanov A, Walker MC, Kullmann DM, Silver RA. Tonically active GABA A receptors: modulating gain and maintaining the tone. Trends Neurosci 27: 262-269, 2004.
58. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368: 144-147, 1994.
59. Shimamoto K, Lebrun B, Yasuda-Kamatani Y, Sakaitani M, Shigeri Y, Yumoto N, Nakajima T. DL-Threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol 53: 195-201, 1998.
60. Sjostrom PJ, Turrigiano GG, Nelson SB. Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron 39: 641-654, 2003.
61. Standaert DG, Landwehrmeyer GB, Kerner JA, Penney JB Jr, Young AB. Expression of NMDAR2D glutamate receptor subunit mRNA in neuro-chemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Mol Brain Res 42: 89-102, 1996.
62. Stocca G, Vicini S. Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J Physiol 507: 13-24, 1998.
63. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37: 173-182, 1991.
64. Suzuki T, Kodama S, Hoshino C, Izumi T, Miyakawa H. A plateau potential mediated by the activation of extrasynaptic NMDA receptors in rat hippocampal CA1 pyramidal neurons. Eur J Neurosci 28: 521-534, 2008.
65. Sveinbjornsdottir S, Sander JW, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe D, Duncan JS. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 16: 165-174, 1993.
66. Tammaro P, Ashcroft FM. A mutation in the ATP-binding site of the Kir6.2 subunit of the KATP channel alters coupling with the SUR2A subunit. J Physiol 584: 743-753, 2007.
67. Tovar KR, Westbrook GL. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19: 4180-4188, 1999.
68. Van Bockstaele EJ, Colago EE. Selective distribution of the NMDA-R1 glutamate receptor in astrocytes and presynaptic axon terminals in the nucleus locus coeruleus of the rat brain: an immunoelectron microscopic study. J Comp Neurol 369: 483-496, 1996.
69. Wang XM, Bausch SB. Effects of distinct classes of N-methyl-D-aspartate receptor antagonists on seizures, axonal sprouting and neuronal loss in vitro: suppression by NR2B-selective antagonists. Neuropharmacology 47: 1008-1020, 2004.
70. Woodhall G, Evans DI, Cunningham MO, Jones RS. NR2B-containing NMDA autoreceptors at synapses on entorhinal cortical neurons. J Neurophysiol 86: 1644-1651, 2001.
71. Yamakura T, Shimoji K. Subunit-and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59: 279-298, 1999.